WallStreetZenWallStreetZen

NASDAQ: INSM
Insmed Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for INSM

Based on 6 analysts offering 12 month price targets for Insmed Inc.
Min Forecast
$37.00+41.38%
Avg Forecast
$46.33+77.05%
Max Forecast
$54.00+106.34%

Should I buy or sell INSM stock?

Based on 6 analysts offering ratings for Insmed Inc.
Strong Buy
Strong Buy
4 analysts 66.67%
Buy
2 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their INSM stock forecasts and price targets.

INSM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Cantor Fitzgerald
Bottom 8%
8
Strong BuyMaintains$54.00+106.34%2023-09-21
Evercore ISI Group
Top 15%
86
BuyMaintains$42.00+60.49%2023-09-07
Bank of America
Bottom 11%
11
Strong BuyMaintains$37.00+41.38%2023-09-06
HC Wainwright & Co.
Bottom 1%
1
BuyReiterates$52.00+98.70%2023-09-06
Guggenheim
Top 3%
98
Strong BuyReiterates$52.00+98.70%2023-09-05Find out why
Morgan Stanley
Bottom 3%
3
Strong BuyReiterates$41.00+56.67%2023-08-04

1 of 1

Forecast return on equity

Is INSM forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is INSM forecast to generate an efficient return on assets?
Company
N/A
Industry
0.07%

INSM revenue growth forecast

How is INSM forecast to perform vs Biotechnology companies and vs the US market?
Company
34.81%
Industry
35.95%
Market
8.15%
INSM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
INSM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

INSM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
INSM$26.17$46.33+77.05%Strong Buy
DNA$1.77$1.25-29.38%Strong Sell
IMGN$14.77$23.00+55.72%Strong Buy
ACAD$23.56$31.09+31.97%Buy
CRSP$45.49$73.08+60.64%Buy
View Top Biotech Stocks

Insmed Stock Forecast FAQ

Is Insmed Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: INSM) stock is to Strong Buy INSM stock.

Out of 6 analysts, 4 (66.67%) are recommending INSM as a Strong Buy, 2 (33.33%) are recommending INSM as a Buy, 0 (0%) are recommending INSM as a Hold, 0 (0%) are recommending INSM as a Sell, and 0 (0%) are recommending INSM as a Strong Sell.

If you're new to stock investing, here's how to buy Insmed stock.

What is INSM's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: INSM) forecast ROE is N/A, which is considered weak.

What is INSM's Price Target?

According to 6 Wall Street analysts that have issued a 1 year INSM price target, the average INSM price target is $46.33, with the highest INSM stock price forecast at $54.00 and the lowest INSM stock price forecast at $37.00.

On average, Wall Street analysts predict that Insmed's share price could reach $46.33 by Sep 21, 2024. The average Insmed stock price prediction forecasts a potential upside of 77.05% from the current INSM share price of $26.17.

What is INSM's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: INSM) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.07%.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.